Adjunctive Glycine for Obsessive Compulsive Disorder
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
New York
-
Orangeburg, New York, United States, 10962
- The Nathan Kline Institute for Psychiatric Research
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Diagnosis of OCD present for at least 1 year
- Male or female, age 18 to 65
- Stable medication regimen for 12 weeks prior to study entry
- at least moderately severe OC symptoms
Exclusion Criteria:
- Active substance use disorder within the last 6 months
- Comorbid schizophrenia, schizoaffective disorder, bipolar disorder, tic disorder, Tourette Disorder, schizotypal personality disorder
- Hoarding as the principal OCD symptom
- Insulin-dependent diabetes mellitus
- Pregnant or breastfeeding
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: A
glycine powder
|
|
|
Placebo Comparator: B
placebo powder
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Y-BOCS (Yale-Brown Obsessive Compulsive Scale)
Time Frame: 12 weeks after baseline
|
12 weeks after baseline
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
NIMC-OC scale
Time Frame: 12 weeks after baseline
|
12 weeks after baseline
|
|
CGI-Improvement
Time Frame: 12 weeks after baseline
|
12 weeks after baseline
|
|
QLS(Quality of Life Scale)
Time Frame: 12 weeks after baseline
|
12 weeks after baseline
|
|
Sheehan Disability Scale
Time Frame: 12 weeks after baseline
|
12 weeks after baseline
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: William M Greenberg, MD, Nathan Kline Institute for Psychiatric Research
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 04I/C06
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.